

Weihaio Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2203910/publications.pdf>

Version: 2024-02-01

23
papers

173
citations

1307594

7
h-index

1372567

10
g-index

25
all docs

25
docs citations

25
times ranked

133
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021, 77, 1549-1558. | 2.7 | 16 |
| 2 | Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2022, 79, 241-250. | 2.7 | 14 |
| 3 | Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. <i>British Journal of General Practice</i> , 2021, 71, e62-e70. | 1.4 | 13 |
| 4 | Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 618816. | 2.4 | 13 |
| 5 | Mean platelet volume/platelet count ratio predicts long-term mortality in patients with infective endocarditis. <i>Biomarkers in Medicine</i> , 2020, 14, 293-302. | 1.4 | 11 |
| 6 | C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial. <i>BMC Medicine</i> , 2021, 19, 44. | 5.5 | 11 |
| 7 | Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. <i>ESC Heart Failure</i> , 2022, 9, 2567-2575. | 3.1 | 10 |
| 8 | Usefulness of CHADS2, R2CHADS2, and CHA2DS2â€VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients. <i>ESC Heart Failure</i> , 2021, 8, 1369-1377. | 3.1 | 9 |
| 9 | Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016009. | 3.7 | 8 |
| 10 | CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 763-772. | 2.6 | 8 |
| 11 | Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 681726. | 2.4 | 7 |
| 12 | Prognostic significance of blood urea nitrogen/creatinine ratio in chronic HFpEF. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13761. | 3.4 | 7 |
| 13 | Angiotensin-Like Protein 7 and Short-Term Mortality in Acute Heart Failure. <i>CardioRenal Medicine</i> , 2020, 10, 116-124. | 1.9 | 6 |
| 14 | Living Alone and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Psychosomatic Medicine</i> , 2021, 83, 470-476. | 2.0 | 6 |
| 15 | Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13401. | 3.4 | 6 |
| 16 | Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 247-253. | 2.6 | 5 |
| 17 | Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 689591. | 2.4 | 5 |
| 18 | Association of hyponatraemia and renal function in type 1 cardiorenal syndrome. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13269. | 3.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Salt restriction and risk of adverse outcomes in heart failure with preserved ejection fraction. <i>Heart</i> , 2022, 108, 1377-1382. | 2.9 | 4 |
| 20 | Prognostic Value of Cysteine-Rich Protein 61 Combined with N-Terminal Pro-B-Type Natriuretic Peptide for Mortality in Acute Heart Failure Patients with and without Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2020, 10, 11-21. | 1.9 | 3 |
| 21 | Ischemic risk in patients with heart failure with preserved ejection fraction: A post hoc analysis of the TOPCAT data. <i>Atherosclerosis</i> , 2022, 344, 1-6. | 0.8 | 3 |
| 22 | Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 579400. | 2.4 | 2 |
| 23 | Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT. <i>ESC Heart Failure</i> , 2020, 7, 3801-3809. | 3.1 | 2 |